Developing a new T cell vaccine to fight malaria
Official title: Human-informed data-driven development of next-generation T cell vaccine against malaria
Funded at University of Queensland · NIH-10696142 · Data updated 2026-11-12
This study is working on a new malaria vaccine that helps your immune system fight off the disease better by finding special parts of the malaria parasite that can boost your body's defenses.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Queensland NIH-funded |
| Lab location | 1 site (Brisbane, Australia) |
| Project start | September 2, 2022 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $476,538 |
| NIH project number | 5R01AI162830-03 |
| Project ID | NIH-10696142 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals living in malaria-endemic regions who are at risk of infection.
✕Less likely to help
Patients who are not at risk of malaria or those who have already been vaccinated against malaria may not benefit from this research.
What this research studies
This research aims to create a next-generation vaccine against malaria by identifying key antigens that stimulate T cell responses. The approach involves screening the complete Plasmodium falciparum parasite proteome to find specific antigens that can trigger protective immunity. By focusing on CD8+ T cells, which play a crucial role in attacking the malaria parasite during its early stages, the research seeks to enhance the effectiveness of malaria vaccination. The ultimate goal is to develop a vaccine that can prevent malaria infections and reduce the disease's global impact.
Why it matters
Potential benefit: If successful, this research could lead to a highly effective malaria vaccine, significantly reducing the number of malaria cases and deaths worldwide.
How similar studies have gone: Previous research has shown promise in developing malaria vaccines using similar approaches, indicating potential for success in this novel investigation.
Where this research is happening
-
University of Queensland
Brisbane, Australia Active
Researchers
- Principal investigator: Doolan, Denise L. — University of Queensland
- Study coordinator: Doolan, Denise L.
Related research
Other NIH-funded projects on the same topics.
-
Digital malaria surveillance in Ethiopia to improve outbreak detection
A collaboration to add a malaria-specific digital module to an existing surveillance system in Africa to help detect and respond to outbreaks faster.
-
Cross-sector partnership uses digital malaria surveillance in Ethiopia
A US-based team will adapt and test a digital malaria surveillance module in SORMAS to help detect and respond to malaria outbreaks in Ethiopia.
-
Malaria control project in Western Kenya to reduce illness and deaths
A large, multi-year effort in western Kenya will help track malaria spread and test ways to prevent transmission so fewer people get sick or die.
-
Optimizing tafenoquine dose to prevent relapse of vivax malaria in Asia
A study tests the best tafenoquine dose to prevent P. vivax malaria relapse in people in East Asia and Oceania.
-
Optimizing tafenoquine dose to prevent P. vivax malaria relapses in Asia
A study to find the best single-dose tafenoquine amount to prevent relapse of P. vivax malaria in people in East Asia and Oceania.
-
Severe malaria and brain risk in children
This grant studies how severe malaria in young children can affect brain development and long-term thinking and behavior, with a focus on kids in Uganda.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.